22NW LP’s Keros Therapeutics KROS Stock Holding History

22NW LP’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-179,000	Closed	-$1.82M	–	23
2025 Q1	$1.82M	Buy	+179,000	New	+$2.08M	1.22%	16

Other funds holding KROS

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

22NW LP's KROS Position: Q2 2025 in Review

22NW LP sold out of Keros Therapeutics (KROS) in Q2 2025, closing a stake of 179,000 shares — an estimated $1.82M sold.

22NW LP first reported a position in KROS in Q1 2025 and held it in 1 quarter. The position peaked at $1.82M in Q1 2025. 139 funds tracked by Wall St. Rank hold KROS as of Q2 2025.

22NW LP reported no remaining Keros Therapeutics position as of Q2 2025 after selling out during the quarter.
22NW LP sold 179,000 Keros Therapeutics shares in Q2 2025, an estimated $1.82M.
22NW LP first reported a position in Keros Therapeutics in Q1 2025 and held it in 1 quarter.
22NW LP's Keros Therapeutics position peaked at $1.82M in Q1 2025.
139 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2025.

Based on 22NW LP's 13F filing for Q2 2025, filed 14 Aug 2025.